Contact Us: | Toll Free No: 888 225 2950 | Phone: +1 407 996 9630 | Fax: +1 407 996 9631
Contact Us

Press Releases

MEDITE Cancer Diagnostics to Launch SureCyteTM C1 Stain Globally at the 29th European Congress of Pathology

Revolutionary product provides clinicians with accelerated, efficient staining process with enhanced digital imaging capabilities Orlando, Fl., July 27, 2017 - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announced today that it will launch…
Read more

MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations

ORLANDO, FL -- (Marketwired) -- 05/10/17 -- MEDITE Cancer Diagnostics, Inc. (MDIT) (the "Company") specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces further restructuring of its organization in Germany to position the Company for revenue growth and…
Read more

MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations

ORLANDO, FL -- (Marketwired) -- 04/28/17 -- MEDITE Cancer Diagnostics, Inc. (MDIT) (the "Company") specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announced the restructuring of its organization in Germany to position the Company for revenue growth and…
Read more

MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial Officer

ORLANDO, FL -- (Marketwired) -- 04/27/17 -- MEDITE Cancer Diagnostics, Inc. (MDIT) (the "Company"), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, today announced the appointment of Susan Weisman as Chief Financial Officer "MEDITE has worked with Susan…
Read more

MEDITE Cancer Diagnostics Appoints Eric M. Goehausen to Board of Directors

ORLANDO, FL -- (Marketwired) -- 03/07/17 -- MEDITE Cancer Diagnostics, Inc. (MDIT) ("MEDITE" or the "Company"), a medical technology company specializing in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases, today announced that Mr. Eric M. Goehausen has been elected…
Read more

MEDITE Cancer Diagnostics, Inc. Reports Second Quarter 32% Revenue Increase and Six Months 2016 Results

Orlando, Fl., August 29, 2016 -  MEDITE Cancer Diagnostics, Inc., (OTCQB:MDIT, the “Company”) specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its second quarter and six months 2016 results. For the three months ended June 30, 2016,…
Read more

MEDITE Cancer Diagnostics, Inc. Reports $9.9 Million in Revenue and Results for 2015

Orlando, Fl., April 13, 2016 - MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT, the “Company”) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its 2015 financial results. The Company reports $9.9 million in revenue for 2015. It successfully…
Read more

MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) To Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz-Carlton in South Beach on Feb. 22, 2016

Orlando, FL., January 17, 2016 - MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT, the “Company”) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at The…
Read more

MEDITE Cancer Diagnostics, Inc. will present at the SeeThruEquity Healthcare Investor Conference on January 11th

Orlando, FL., January 7, 2016 - MEDITE Cancer Diagnostics, Inc., (OTC:MDIT, the “Company”) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual…
Read more

Medite Cancer Diagnostics, Inc. Reports a Profitable Third Quarter and Nine Month 2015 Results

Orlando, Fl., November 17, 2015 - MEDITE Cancer Diagnostics, Inc., (OTCQB:MDIT, the “Company”) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results. The Company reports $2.7 million of revenues and…
Read more

Investment by UNIC Technologies CEO Dr. Zhongxi Zheng for 5.06% of MEDITE Cancer Diagnostics, Inc. Highlights Digital Cancer Diagnostic Strategy

Orlando, FL., September 9, 2015 - MEDITE Cancer Diagnostics, Inc., (OTC/QB: MDIT) specializing in the development, manufacturing, and marketing of immuno-assays and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces an investment by UNIC Medical, Inc.‘s Chairman and UNIC Technologies, Inc.’s CEO, Dr. Zhongxi Zheng, an MD in…
Read more

MEDITE Cancer Diagnostics, Inc. successfully obtained Mexican Tender for 31 Stainers and First Delivery of new Manual Microtome to China

Orlando, FL., August 27, 2015 - MEDITE Cancer Diagnostics, Inc., (OTC/QB: MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its Mexican distributor, ATYDE won a public tender for delivery of 31 MEDITE tissue staining machines with…
Read more